OBJECTIVE: To investigate the effects of rosuvastatin combined with tirofiban on serum inflammatory factors and renal function in acute coronary syndrome patients with diabetes after percutaneous coronary intervention (PCI).METHODS: A total of 120 acute coronary syndrome patients with diabetes receiving PCI selected from cardiology department of our hospital during Apr. 2014-Mar. 2015 were divided into control group and observation group according to random number table, with 60 cases in each group. Except for routine treatment, control group was given Rosuvastatin calcium tablets orally after surgery (10 mg each day, for consecutive 7 d); observation group was given Rosuvastatin calcium tablets orally before and after surgery (20 mg before surgery; 10 mg each day after surgery, for consecutive 7 d), and then given Tirohydrochloric acid sodium chloride injection during surgery [10 μg/kg intravenously, 0. 15 μg/(kg· min) with intravenous pump for 36 h]. Clinical efficacies of 2 groups were compared. The changes of serum inflammatory factors (TNF-α, IL-6, IL-10) and renal function indexes (Scr, CysC, eGFR), the incidence of radiographic contrast nephropathy were compared before surgery and 24, 72 h after surgery. The occurrence of cardiovascular events was followed up for one year. RESULTS: There were no statistical significance in baseline information between 2 groups before treatment (P>0. 05). The number of complete remission case and total response rate in observation group were increased significantly higher than control group (P0. 05).观察组患者治疗后完全缓解例数和总有效率明显高于对照组(P<0. 05),无效例数明显低于对照组(P<0. 05).与术前比较,两组患者术后24、72h的血清炎症因子水平均明显降低,对照组患者术后24、72h和观察组患者术后24h的Scr和CysC水平明显升高, eGFR水平明显降低,观察组患者术后72 h仅CysC水平明显升高,以上差异均有统计学意义(P<0. 05).观察组患者的血清炎症因子和肾功能指标改善效果均较对照组更明显(P<0. 05),造影剂肾病发生率明显低于对照组(P<0. 05);随访1年的心绞痛发生率和心血管事件总发生率明显低于对照组(P<0. 05).结论:瑞舒伐他汀联合替罗非班可促进急性冠状动脉综合征并发糖尿病患者PCI术后的肾功能恢复,降低血清炎症因子水平,降低造影剂肾病发生率和治疗后心血管事件发生率,与瑞舒伐他汀单用存在差异.
展开▼
